"With the Lenovo platform in place, Jiangxi Jemincare has the infrastructure required to support big data analytics and drive long-term, sustainable growth. The high-performance solution will help the company to gain a deeper view of business performance, identify opportunities, and generate reports faster than ever—enabling leaders to make more effective decisions that minimize risk and increase profitability."
At-a-Glance
- Customer: Jiangxi Jemincare
- Industry: Healthcare,None
- Product Family: lenovo:product-group-and-series/L110056/L210089
- Region: China
- Processor: Intel
- Topic: Hyperconverged Infrastructure
Seizing a greater share of the rapidly expanding pharmaceutical market.
Founded in 1999, Jiangxi Jemincare Group Co. Ltd. develops and manufactures modern Chinese medicines and healthcare products. The company operates research centers and industrial plants in the cities of Jiangxi, Beijing, Shanghai, Jiangsu, and Zhejiang, as well as international drug development teams, and achieves annual revenues of more than US$3.6 billion.
In 2019, the Chinese pharmaceutical sector expanded by almost 9% to become worth US$359 billion; by 2026, analysts believe this figure will almost double to US$650 billion. Jiangxi Jemincare aims to increase its share of this rapidly expanding marketplace and to strengthen its position as one of the ten largest pharmaceutical companies operating in China.
Want to share your own Lenovo success story?
Fill out this form and a member of the Customer Marketing Team will contact you.